Fate Therapeutics

FATE · NASDAQ

$2.06+$0.20 (+10.75%)TodayMarket closed · Oct 20, 7:44 PM ET

Prev close $1.86

About FATE

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. The company is headquartered in San Diego, California and currently employs 161 full-time employees. The company went IPO on 2013-10-01. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.

Employees: 161
Headquarters: San Diego, California
Listed: Oct 1, 2013
Sector: Health Care
Industry: Biotechnology
Website: fatetherapeutics.com

Leadership

Fate Therapeutics executives
Name	Title	Since	Age
William Rastetter	—	—	77
Bahram Valamehr	—	2018	48
Kamal Adawi	—	—	46
Cindy Tahl	—	—	52
Matthew Abernethy	—	—	45
Shefali Agarwal	—	—	52
Robert Epstein	—	—	70
Karin Jooss	—	—	60
Michael Lee	—	—	46
Xu Yuan	—	—	57

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Fate Therapeutics suppliers and customers
Company	Relationship	Country	Correlation
CryoPort CYRX	Supplier	US	0.72
Johnson & Johnson JNJ	Supplier and customer	US	-0.32
Ono Pharmaceutical	Supplier and customer	JP	-0.76
Juno Therapeutics, Inc. JUNO	Supplier and customer	US	—
Dana-Farber Cancer Institute, Inc.	Supplier and customer	US	—
Inscripta, Inc.	Supplier and customer	US	—
J. David Gladstone Institutes	Supplier and customer	US	—
Memorial Sloan-Kettering Cancer Center	Supplier and customer	US	—
Scripps Research Institute	Supplier and customer	US	—
University of Minnesota	Supplier and customer	US	—

Similar companies

Companies in the same industry as Fate Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.